Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Bertrand, Pollet"'
Autor:
Véronique Dorvaux, Marc Delord, Marc Muller, Melanie Mercier, Hacene Zerazhi, Jacques Chapiro, Eric Jourdan, Laurence Legros, Françoise Rigal-Huguet, Iona Vaida, François Guilhot, Alberto Santagostino, Claude Preudhomme, Joelle Guilhot, Valérie Coiteux, Jean-Michel Miclea, Jean-Jacques Kiladjian, Emmanuel Gyan, Aude Charbonnier, Amélie Penot, Eric Deconinck, Franck E. Nicolini, Gabriel Etienne, Hyacinthe Johnson-Ansah, Jean-Claude Chomel, Kamel Ghomari, Nathalie Cambier, Delphine Lebon, Viviane Dubruille, Sylvie Glaisner, Philippe Rousselot, Loïc Fouillard, Alain Delmer, Bertrand Joly, Pascal Lenain, Claude-Eric Bulabois, Martine Escoffre Barbe, Christian Berthou, Isabelle Plantier, Delphine Rea, Marc G. Berger, Magda Alexis, Francois-Xavier Mahon, Pascale Cony-Makhoul, Ludovic Lhermitte, Lydia Roy, Jean-Michel Cayuela, Denis Caillot, Anne Vekhoff, Martine Gardembas, Bertrand Pollet, Agnès-Paule Guerci-Bresler, Yazid Arkam, Hervé Maisonneuve, Frédéric Maloisel
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-020-01117-w⟩
Leukemia, Springer Nature, 2021, ⟨10.1038/s41375-020-01117-w⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-020-01117-w⟩
Leukemia, Springer Nature, 2021, ⟨10.1038/s41375-020-01117-w⟩
The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine (AraC), and IM 400 mg + pegylated interferon alpha2a (PegIFN-α2a) for the front-line treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e82d474ec7e8650bf9829473b30a0c5
https://hal.uca.fr/hal-03122967
https://hal.uca.fr/hal-03122967
Autor:
Francois, Guilhot, Françoise, Rigal-Huguet, Joëlle, Guilhot, Agnès-Paule, Guerci-Bresler, Frédéric, Maloisel, Delphine, Rea, Valérie, Coiteux, Martine, Gardembas, Christian, Berthou, Anne, Vekhoff, Eric, Jourdan, Marc, Berger, Loïc, Fouillard, Magda, Alexis, Laurence, Legros, Philippe, Rousselot, Alain, Delmer, Pascal, Lenain, Martine, Escoffre Barbe, Emmanuel, Gyan, Claude-Eric, Bulabois, Viviane, Dubruille, Bertrand, Joly, Bertrand, Pollet, Pascale, Cony-Makhoul, Hyacinthe, Johnson-Ansah, Melanie, Mercier, Denis, Caillot, Aude, Charbonnier, Jean-Jacques, Kiladjian, Jacques, Chapiro, Amélie, Penot, Véronique, Dorvaux, Iona, Vaida, Alberto, Santagostino, Lydia, Roy, Hacene, Zerazhi, Eric, Deconinck, Herve, Maisonneuve, Isabelle, Plantier, Delphine, Lebon, Yazid, Arkam, Nathalie, Cambier, Kamel, Ghomari, Jean-Michel, Miclea, Sylvie, Glaisner, Jean-Michel, Cayuela, Jean-Claude, Chomel, Marc, Muller, Ludovic, Lhermitte, Marc, Delord, Claude, Preudhomme, Gabriel, Etienne, François-Xavier, Mahon, Franck-Emmanuel, Nicolini
Publikováno v:
Leukemia. 35(8)
The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine (AraC), and IM 400 mg + pegylated interferon alpha2a (PegIFN-α2a) for the front-line treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5fc8a6e6e69b503d2820214392aae2a6
https://pubmed.ncbi.nlm.nih.gov/33483613
https://pubmed.ncbi.nlm.nih.gov/33483613
